We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
Read MoreHide Full Article
Key Takeaways
ANI Pharmaceuticals posted 36% Rare Disease and Brands growth in Q1 2026 led by Cortrophin and Iluvien.
ANIP guided 2026 Iluvien sales of $78M-$83M after 2025 reimbursement and inventory disruptions.
ANI Pharmaceuticals expects 10-15 generic launches in 2026 to support steady cash-flow generation.
ANI Pharmaceuticals’ (ANIP - Free Report) business is moving deeper into specialty, with Rare Disease and Brands now positioned as the primary growth driver. The first quarter of 2026 reinforced that tilt, with specialty momentum supported by Cortrophin Gel and a growing contribution from royalties and other revenue streams.
At the same time, management is treating 2025 as an operational reset for the retina franchise after reimbursement and inventory disruptions. The 2026 playbook centers on restoring Iluvien growth, keeping generics steady, and managing mix-driven margin pressure as royalties expand.
ANIP’s Portfolio Shift Toward Specialty and Royalties
ANI’s strategic repositioning is anchored in Rare Disease and Brands, with Cortrophin Gel as the core specialty engine and Iluvien as the second pillar in retina. This shift is visible in segment performance, where fiscal 2025 revenue mix leaned modestly toward Rare Disease and Brands, while Generics and Other remained a substantial contributor.
In the first quarter of 2026, the company reported Rare Disease and Brands net revenues of $128.2 million, up 36% year over year, led by Cortrophin and Iluvien. Generics and Other delivered $109.2 million, up 6%.
Royalties and other revenue became more meaningful in the quarter. ANI posted $21.5 million in brand royalties and other revenues, tied to an upfront payment and early royalty income from a licensing agreement with Harmony Biosciences (HRMY - Free Report) .
ANI Pharmaceuticals’ Retina Reset After the Alimera Deal
The September 2024 acquisition of Alimera Sciences broadened ANI’s specialty profile by adding Iluvien and Yutiq. The deal diversified revenue away from a single-product reliance on Cortrophin and expanded ANI’s ophthalmology presence and international footprint.
In fiscal 2025, Iluvien and Yutiq generated $74.9 million in combined revenues, and the company recorded international revenues of $30.9 million from direct operations and partnerships.
Even with the diversification benefits, the retina franchise faced headwinds in 2025 tied to reimbursement challenges and elevated inventory levels at physician offices. Those factors shaped management’s “reset year” framing and set up the commercial changes now carrying into 2026.
ANIP’s Iluvien Consolidation Strategy for Two Indications
A key 2025 change was commercial simplification through brand consolidation. ANI streamlined the portfolio by consolidating Iluvien and Yutiq under a unified Iluvien brand.
The strategy is designed to support a single product promoted across two indications: diabetic macular edema and chronic non-infectious uveitis affecting the posterior segment of the eye. This approach aims to reduce complexity in messaging and field execution while improving physician familiarity across the broader use case.
Competitive dynamics make that simplification more important. In retina, Iluvien competes with AbbVie (ABBV - Free Report) , whose Ozurdex overlaps across both indications, and with Regeneron Pharmaceuticals (REGN - Free Report) , whose Eylea and Eylea HD are prominent therapies in diabetic macular edema.
Management expects a return to growth in the retina franchise in 2026 after market access disruption in 2025, including funding constraints affecting patient assistance programs for Medicare beneficiaries.
For 2026, ANI guided Iluvien sales to $78 million to $83 million, implying 4% to 11% year-over-year growth off the 2025 base. The commercial plan emphasizes peer-to-peer education, updated marketing materials, and expanding physician familiarity across both indications.
The recovery thesis also leans on under-penetration. Management estimates addressable patient populations are at least 10 times larger than the current number of patients receiving treatment, which supports the longer runway if execution improves and access normalizes.
ANIP’s Generics as a Cash-Flow Engine, Not the Headline
Generics is framed as a durable cash flow foundation rather than the primary growth narrative. In fiscal 2025, the generics business produced $384 million in revenue, up about 28% year over year, and management highlighted the segment’s differentiated development and manufacturing capabilities.
In the first quarter of 2026, Generics and Other grew 6% year over year to $109.2 million, supported by new launches and strength from a partnered generic product launched in the third quarter of 2025.
The cadence remains central to the segment’s role. Management said six generic products were launched year to date and reiterated expectations for 10 to 15 new generic launches in 2026, with an emphasis on niche, lower-competition opportunities.
ANI Pharmaceuticals’ Competition and Customer Concentration Risks
Competition is intensifying across ANI’s specialty markets. In rare disease, Cortrophin’s primary competitor is Acthar Gel, marketed by Keenova Therapeutics, and management highlighted that Acthar is also seeing similar momentum in sales growth.
In retina, Iluvien faces major branded competitors across both indications and in diabetic macular edema specifically, including AbbVie and Regeneron. As ANI scales specialty revenue, execution will increasingly be judged against these entrenched products and prescribing patterns.
Customer concentration adds another layer of risk. In 2025, three wholesale customers accounted for 53% of total net revenues and represented 64% of accounts receivable, leaving ANI exposed to distributor purchasing leverage and industry consolidation trends.
ANIP’s “Watch List” for 2026 Execution
The key operational checkpoints are straightforward. First is Cortrophin growth against the reaffirmed 2026 guidance range of $540 million to $575 million, following first-quarter net revenues of $75.1 million that were impacted by insurance re-verification seasonality.
Second is Iluvien’s return-to-growth trajectory against the $78 million to $83 million outlook, with commercial actions focused on education and updated promotion after 2025 access headwinds.
Third is the generics launch cadence, with management targeting 10 to 15 launches in 2026. Investors will also be watching gross margin pressure from a richer mix of royalty-bearing products, alongside capital allocation decisions such as the $100 million repurchase authorization through May 2029 and business development ambitions, against reported gross leverage of 2.6x and net leverage of 1.3x as of March 31, 2026.
View the Zacks #1 Rank List
Image: Bigstock
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
Key Takeaways
ANI Pharmaceuticals’ (ANIP - Free Report) business is moving deeper into specialty, with Rare Disease and Brands now positioned as the primary growth driver. The first quarter of 2026 reinforced that tilt, with specialty momentum supported by Cortrophin Gel and a growing contribution from royalties and other revenue streams.
At the same time, management is treating 2025 as an operational reset for the retina franchise after reimbursement and inventory disruptions. The 2026 playbook centers on restoring Iluvien growth, keeping generics steady, and managing mix-driven margin pressure as royalties expand.
ANIP’s Portfolio Shift Toward Specialty and Royalties
ANI’s strategic repositioning is anchored in Rare Disease and Brands, with Cortrophin Gel as the core specialty engine and Iluvien as the second pillar in retina. This shift is visible in segment performance, where fiscal 2025 revenue mix leaned modestly toward Rare Disease and Brands, while Generics and Other remained a substantial contributor.
In the first quarter of 2026, the company reported Rare Disease and Brands net revenues of $128.2 million, up 36% year over year, led by Cortrophin and Iluvien. Generics and Other delivered $109.2 million, up 6%.
Royalties and other revenue became more meaningful in the quarter. ANI posted $21.5 million in brand royalties and other revenues, tied to an upfront payment and early royalty income from a licensing agreement with Harmony Biosciences (HRMY - Free Report) .
ANI Pharmaceuticals’ Retina Reset After the Alimera Deal
The September 2024 acquisition of Alimera Sciences broadened ANI’s specialty profile by adding Iluvien and Yutiq. The deal diversified revenue away from a single-product reliance on Cortrophin and expanded ANI’s ophthalmology presence and international footprint.
In fiscal 2025, Iluvien and Yutiq generated $74.9 million in combined revenues, and the company recorded international revenues of $30.9 million from direct operations and partnerships.
Even with the diversification benefits, the retina franchise faced headwinds in 2025 tied to reimbursement challenges and elevated inventory levels at physician offices. Those factors shaped management’s “reset year” framing and set up the commercial changes now carrying into 2026.
ANIP’s Iluvien Consolidation Strategy for Two Indications
A key 2025 change was commercial simplification through brand consolidation. ANI streamlined the portfolio by consolidating Iluvien and Yutiq under a unified Iluvien brand.
The strategy is designed to support a single product promoted across two indications: diabetic macular edema and chronic non-infectious uveitis affecting the posterior segment of the eye. This approach aims to reduce complexity in messaging and field execution while improving physician familiarity across the broader use case.
Competitive dynamics make that simplification more important. In retina, Iluvien competes with AbbVie (ABBV - Free Report) , whose Ozurdex overlaps across both indications, and with Regeneron Pharmaceuticals (REGN - Free Report) , whose Eylea and Eylea HD are prominent therapies in diabetic macular edema.
ANI Pharmaceuticals, Inc. Price and EPS Surprise
ANI Pharmaceuticals, Inc. price-eps-surprise | ANI Pharmaceuticals, Inc. Quote
ANI Pharmaceuticals’ 2026 Iluvien Recovery Plan
Management expects a return to growth in the retina franchise in 2026 after market access disruption in 2025, including funding constraints affecting patient assistance programs for Medicare beneficiaries.
For 2026, ANI guided Iluvien sales to $78 million to $83 million, implying 4% to 11% year-over-year growth off the 2025 base. The commercial plan emphasizes peer-to-peer education, updated marketing materials, and expanding physician familiarity across both indications.
The recovery thesis also leans on under-penetration. Management estimates addressable patient populations are at least 10 times larger than the current number of patients receiving treatment, which supports the longer runway if execution improves and access normalizes.
ANIP’s Generics as a Cash-Flow Engine, Not the Headline
Generics is framed as a durable cash flow foundation rather than the primary growth narrative. In fiscal 2025, the generics business produced $384 million in revenue, up about 28% year over year, and management highlighted the segment’s differentiated development and manufacturing capabilities.
In the first quarter of 2026, Generics and Other grew 6% year over year to $109.2 million, supported by new launches and strength from a partnered generic product launched in the third quarter of 2025.
The cadence remains central to the segment’s role. Management said six generic products were launched year to date and reiterated expectations for 10 to 15 new generic launches in 2026, with an emphasis on niche, lower-competition opportunities.
ANI Pharmaceuticals’ Competition and Customer Concentration Risks
Competition is intensifying across ANI’s specialty markets. In rare disease, Cortrophin’s primary competitor is Acthar Gel, marketed by Keenova Therapeutics, and management highlighted that Acthar is also seeing similar momentum in sales growth.
In retina, Iluvien faces major branded competitors across both indications and in diabetic macular edema specifically, including AbbVie and Regeneron. As ANI scales specialty revenue, execution will increasingly be judged against these entrenched products and prescribing patterns.
Customer concentration adds another layer of risk. In 2025, three wholesale customers accounted for 53% of total net revenues and represented 64% of accounts receivable, leaving ANI exposed to distributor purchasing leverage and industry consolidation trends.
ANIP’s “Watch List” for 2026 Execution
The key operational checkpoints are straightforward. First is Cortrophin growth against the reaffirmed 2026 guidance range of $540 million to $575 million, following first-quarter net revenues of $75.1 million that were impacted by insurance re-verification seasonality.
Second is Iluvien’s return-to-growth trajectory against the $78 million to $83 million outlook, with commercial actions focused on education and updated promotion after 2025 access headwinds.
Third is the generics launch cadence, with management targeting 10 to 15 launches in 2026. Investors will also be watching gross margin pressure from a richer mix of royalty-bearing products, alongside capital allocation decisions such as the $100 million repurchase authorization through May 2029 and business development ambitions, against reported gross leverage of 2.6x and net leverage of 1.3x as of March 31, 2026.
ANIP’s Zacks Rank
ANI Pharmaceuticals currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.